OBJECTIVES: The aims of this study were to compare prevalence rates of human papillomavirus (HPV) in young women before and after HPV vaccine introduction to determine the following: (1) whether vaccine-type HPV infection decreased, (2) whether there was evidence of herd protection, and (3) whether there was evidence for type-replacement (increased prevalence of nonvaccine-type HPV). METHODS: Young women 13 to 26 years of age who had had sexual contact were recruited from 2 primary care clinics in 2006-2007 for a prevaccination surveillance study (N = 368, none were vaccinated) and 2009-2010 for a postvaccination surveillance study (N = 409, 59% were vaccinated). Participants completed a questionnaire and were tested for cervicovaginal HPV DNA. HPV prevalence rates were compared in the pre- versus postsurveillance studies by using χ(2) tests. Propensity score weighting was used to balance differences in covariates between the 2 surveillance studies. RESULTS: The mean age was ∼19 years for both groups of participants and most were African American and non-Hispanic. After propensity score weighting, the prevalence rate for vaccine-type HPV decreased substantially (31.7%-13.4%, P < .0001). The decrease in vaccine-type HPV not only occurred among vaccinated (31.8%-9.9%, P < .0001) but also among unvaccinated (30.2%-15.4%, P < .0001) postsurveillance study participants. Nonvaccine-type HPV increased (60.7%-75.9%, P < .0001) for vaccinated postsurveillance study participants. CONCLUSIONS: Four years after licensing of the quadrivalent HPV vaccine, there was a substantial decrease in vaccine-type HPV prevalence and evidence of herd protection in this community. The increase in nonvaccine-type HPV in vaccinated participants should be interpreted with caution but warrants further study.
OBJECTIVES: The aims of this study were to compare prevalence rates of human papillomavirus (HPV) in young women before and after HPV vaccine introduction to determine the following: (1) whether vaccine-type HPV infection decreased, (2) whether there was evidence of herd protection, and (3) whether there was evidence for type-replacement (increased prevalence of nonvaccine-type HPV). METHODS: Young women 13 to 26 years of age who had had sexual contact were recruited from 2 primary care clinics in 2006-2007 for a prevaccination surveillance study (N = 368, none were vaccinated) and 2009-2010 for a postvaccination surveillance study (N = 409, 59% were vaccinated). Participants completed a questionnaire and were tested for cervicovaginal HPV DNA. HPV prevalence rates were compared in the pre- versus postsurveillance studies by using χ(2) tests. Propensity score weighting was used to balance differences in covariates between the 2 surveillance studies. RESULTS: The mean age was ∼19 years for both groups of participants and most were African American and non-Hispanic. After propensity score weighting, the prevalence rate for vaccine-type HPV decreased substantially (31.7%-13.4%, P < .0001). The decrease in vaccine-type HPV not only occurred among vaccinated (31.8%-9.9%, P < .0001) but also among unvaccinated (30.2%-15.4%, P < .0001) postsurveillance study participants. Nonvaccine-type HPV increased (60.7%-75.9%, P < .0001) for vaccinated postsurveillance study participants. CONCLUSIONS: Four years after licensing of the quadrivalent HPV vaccine, there was a substantial decrease in vaccine-type HPV prevalence and evidence of herd protection in this community. The increase in nonvaccine-type HPV in vaccinated participants should be interpreted with caution but warrants further study.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: Lauri E Markowitz; Susan Hariri; Elizabeth R Unger; Mona Saraiya; S Deblina Datta; Eileen F Dunne Journal: Vaccine Date: 2010-02-25 Impact factor: 3.641
Authors: Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein Journal: Pediatrics Date: 2005-09 Impact factor: 7.124
Authors: Rekha Pai; Matthew R Moore; Tamara Pilishvili; Robert E Gertz; Cynthia G Whitney; Bernard Beall Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226
Authors: Chelse Spinner; Lili Ding; David I Bernstein; Darron R Brown; Eduardo L Franco; Courtney Covert; Jessica A Kahn Journal: Pediatrics Date: 2019-01-22 Impact factor: 7.124
Authors: Sylvia L Ranjeva; Edward B Baskerville; Vanja Dukic; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano; Greg Dwyer; Sarah Cobey Journal: Proc Natl Acad Sci U S A Date: 2017-12-05 Impact factor: 11.205
Authors: Joseph E Tota; Frank Struyf; Marko Merikukka; Paula Gonzalez; Aimée R Kreimer; Dan Bi; Xavier Castellsagué; Newton S de Carvalho; Suzanne M Garland; Diane M Harper; Naveen Karkada; Klaus Peters; Willy A J Pope; Carolina Porras; Wim Quint; Ana Cecilia Rodriguez; Mark Schiffman; John Schussler; S Rachel Skinner; Júlio Cesar Teixeira; Cosette M Wheeler; Rolando Herrero; Allan Hildesheim; Matti Lehtinen Journal: J Natl Cancer Inst Date: 2017-01-28 Impact factor: 13.506
Authors: Mónica Saccucci; Eduardo L Franco; Lili Ding; David I Bernstein; Darron Brown; Jessica A Kahn Journal: Sex Transm Dis Date: 2018-04 Impact factor: 2.830
Authors: Courtney Covert; Lili Ding; Darron Brown; Eduardo L Franco; David I Bernstein; Jessica A Kahn Journal: Hum Vaccin Immunother Date: 2019-02-20 Impact factor: 3.452
Authors: Dana Whittemore; Lili Ding; Lea E Widdice; Darron A Brown; David I Bernstein; Eduardo L Franco; Jessica A Kahn Journal: J Womens Health (Larchmt) Date: 2016-10-18 Impact factor: 2.681
Authors: Jessica A Kahn; Lea E Widdice; Lili Ding; Bin Huang; Darron R Brown; Eduardo L Franco; David I Bernstein Journal: Clin Infect Dis Date: 2016-09-20 Impact factor: 9.079